ActiveCap II - Portuguese Growth Fund invests in PMH

The investment by ActiveCap II in PMH underscores a strategic opportunity for both parties to capitalize on PMH's existing strengths and growth potential within the healthcare sector. With nearly 70% of its production exported to key European markets, PMH is well-positioned for international expansion. The primary rationale behind this buyout is to support PMH’s growth strategy by enhancing its operational efficiency through process automation and scaling into new geographies. ActiveCap II's financial backing will enable PMH to accelerate its product development cycle, improve manufacturing processes, and expand its market reach beyond the European Union. The transaction mechanics are straightforward but details on financing structure and valuation multiples remain undisclosed. Notably, Forvis Mazars served as the buy-side advisor for this deal, while legal counsel was provided by VPBG Advogados. The lack of specific financial terms suggests that the investment may be structured to preserve operational flexibility and align with PMH's long-term strategic goals. From a competitive standpoint, ActiveCap’s involvement could shift dynamics in Portugal's medical device industry. By strengthening PMH's technological capabilities and market presence, this deal could challenge existing players and attract more international attention towards Portuguese healthcare innovations. The investment also signals potential for increased private equity activity in high-growth sectors with robust export profiles. Looking ahead, key risks include the ability to integrate new technologies smoothly without disrupting current operations and maintaining strong relationships with existing European clients amidst market volatility. PMH's roadmap includes a focus on process automation and international expansion, which presents significant growth opportunities but also requires careful management of resource allocation and strategic partnerships to ensure successful execution of its 2026–2030 business plan.